| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
48 |
| Employees |
469 |
| Revenues (TTM) (Millions $) |
162 |
| Net Income (TTM) (Millions $) |
-166 |
| Cash Flow (TTM) (Millions $) |
-23 |
| Capital Exp. (TTM) (Millions $) |
21 |
Business Description
NanoString Technologies Inc.
is a leading diagnostic and biotechnology company that specializes in the development and commercialization of molecular diagnostic tests and genomic research tools.
The company uses a proprietary technology called the nCountere Analysis System that offers high levels of precision, sensitivity and reproducibility in detecting and quantifying nucleic acids.
The nCountere Analysis System provides a unique solution to understanding the biology of diseases at a molecular level.
It allows researchers to simultaneously measure the expression levels of hundreds of genes, coding and non-coding RNA species, and copy number variations within a single sample.
This powerful technology doesnet require any amplification or labeling, making it faster than other methods, while still providing high-resolution data.
NanoString Technologiese product portfolio includes several diagnostic assays in the areas of clinical oncology, immunology, neurology, and infectious disease.
The companyes flagship product is the Prosignae Breast Cancer Prognostic Gene Signature Assay, which is FDA-approved for use in postmenopausal women with early-stage breast cancer.
The test helps clinicians to determine which patients may not require chemotherapy after surgery, thereby minimizing the risk of unnecessary treatment.
In addition to its diagnostic assays, NanoString Technologies also provides a range of research tools including the nCountere Analysis System, gene expression panels and assays, protein array products, and digital spatial profiling platform for spatially resolved tissue analysis.
NanoString Technologies have exclusive collaborations with major pharmaceutical companies such as Merck, Pfizer, and Biogen, who use the companyes technology to develop new therapeutics and clinical biomarkers.
NanoString Technologies went public in 2013, and currently has its headquarters in Seattle, Washington.
The company has several offices worldwide, including in Europe and Asia-Pacific.
It continues to lead innovation in the genomics industry with its state-of-the-art technology and diagnostic solutions.
Company Address: 530 Fairview Avenue North Seattle 98109 WA
Company Phone Number: 378-6266 Stock Exchange / Ticker: NASDAQ NSTG
|
%
9.68%